Third-Party Testing Labs Compared: Janoshik, JPS, and Chemyo
In the unregulated world of research peptides and SARMs, third-party testing serves as the primary quality assurance mechanism available to researchers. Without FDA oversight of these compounds for human use, independent laboratory analysis becomes the critical link between manufacturer claims and actual product composition. Understanding the differences between testing providers — their methodologies, limitations, and reputations — is essential for anyone conducting legitimate peptide research.
This article examines three names that frequently appear in peptide and SARM testing discussions: Janoshik Analytical, JPS (Jade Pearl Scientific), and Chemyo's in-house testing program. Each operates under a different model, and understanding these distinctions can help researchers evaluate certificates of analysis (COAs) more critically.
Why Third-Party Testing Matters
The research peptide market exists in a regulatory gray zone. Compounds sold "for research purposes only" are not subject to the same manufacturing standards as pharmaceutical products. Studies have repeatedly demonstrated that this leads to significant quality concerns.
A landmark analysis by Mottram et al., 2015 found that a substantial proportion of SARMs sold online contained compounds other than what was listed on the label, contained no active ingredient at all, or had quantities that deviated significantly from label claims. More recently, Van Wagoner et al., 2017 published findings in JAMA showing that only about 52% of SARMs products contained the actual SARM listed on the label.
These findings underscore why independent verification is not optional — it is the minimum standard for credible research. A certificate of analysis is only as reliable as the laboratory that produced it, and the methodology behind it.
Janoshik Analytical
Janoshik Analytical is a Czech Republic-based independent testing laboratory that has become one of the most widely referenced names in the peptide and performance-enhancing compound testing space. Founded by Michal Janošík, the lab offers direct-to-consumer testing, meaning individual researchers and vendors can submit samples for analysis.
Janoshik primarily uses high-performance liquid chromatography (HPLC) for purity analysis, which is the gold standard for quantitative assessment of peptide and small-molecule purity. The lab also offers mass spectrometry (MS) for compound identification and has expanded services to include testing for heavy metals, bacterial endotoxins, and solvent residuals.
Key characteristics of Janoshik's service include:
The primary strength of Janoshik is accessibility. For independent researchers, having the ability to verify a vendor's claims without needing institutional affiliation is valuable. However, it is worth noting that Janoshik operates as a private commercial laboratory, not an ISO 17025-accredited testing facility. This distinction matters: accreditation involves regular external audits of procedures, equipment calibration, and staff competence by recognized bodies, as outlined by the International Organization for Standardization.
This does not mean Janoshik's results are unreliable — many in the community have found them consistent and reproducible. But researchers should understand the difference between commercial testing and accredited testing when evaluating confidence levels.
JPS (Jade Pearl Scientific)
Jade Pearl Scientific (JPS) is a newer entrant to the peptide testing landscape, positioning itself as a US-based analytical testing service. JPS has gained traction particularly within the peptide research community on forums and social media platforms where users share COA results.
JPS offers services including:
One area where JPS has attempted to differentiate itself is in peptide-specific testing protocols. Peptides present unique analytical challenges compared to small molecules. Their purity by HPLC can be influenced by factors such as the choice of column, mobile phase, gradient conditions, and detection wavelength. Verbeke et al., 2012 reviewed HPLC methodologies for peptide analysis and highlighted how seemingly minor method variations can produce different apparent purity values.
JPS has been more vocal about tailoring analytical methods specifically to the peptides being tested, rather than applying a single generic HPLC method across all compounds. This is a meaningful methodological consideration — a method optimized for BPC-157 may not be ideal for analyzing a longer-chain peptide like CJC-1295.
However, as with Janoshik, researchers should inquire about accreditation status and specific method validation data. Transparency about method parameters — column type, gradient profile, reference standards used — adds credibility to any COA. A result stating "98.5% purity by HPLC" is far more informative when accompanied by the full method description.
Chemyo's Testing Program
Chemyo occupies a different position in this landscape. Unlike Janoshik and JPS, which are independent testing laboratories, Chemyo is primarily a research compound vendor that has built its brand around transparency and testing. Chemyo publishes COAs for its products, but these results come from a combination of internal quality control and outsourced third-party testing.
Chemyo has publicly stated that it uses external laboratories for verification, and the company has been noted for publishing more detailed COAs than many competitors. Their testing program typically includes:
The fundamental distinction here is one of independence versus vendor-affiliated testing. When a vendor commissions and publishes its own testing results, the incentive structure differs from when an independent third party tests a blind sample. This is not unique to Chemyo — it is a structural consideration for any vendor-published COA in any industry.
Research on supplement testing integrity illustrates this concern. Tucker et al., 2018 found that dietary supplement testing programs sometimes failed to detect adulteration or contamination when the testing was commissioned by the manufacturer. Independent, blinded testing — where the lab does not know the expected result — is considered more robust from a scientific integrity standpoint.
That said, Chemyo's willingness to publish COAs at all sets it apart from many vendors who provide no testing documentation whatsoever. The ideal approach for researchers is to treat vendor-supplied COAs as a starting point and verify with independent testing when the research demands high confidence.
Comparing Methodologies and Limitations
All three entities rely on HPLC as their primary analytical tool, which is appropriate. HPLC remains the standard method for peptide purity assessment, as noted in pharmacopeial guidelines from the United States Pharmacopeia (USP). However, several limitations apply universally:
Researchers conducting critical work should consider requesting or performing orthogonal testing — using multiple independent analytical methods to build a complete quality picture. Pace et al., 2014 demonstrated how combining HPLC with amino acid analysis provides a more accurate assessment of true peptide content than either method alone.
How to Evaluate a COA
Regardless of which lab produced a certificate of analysis, researchers should look for several key indicators of quality: